Skip to main content
HYFT
NASDAQ Life Sciences

MindWalk Launches ReefIQ™ AI Platform for Enhanced Drug Discovery

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.8
Mkt Cap
$84.081M
52W Low
$0.51
52W High
$3.246
52W Position info
253% above low
Off High info
45% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

HYFT has more than doubled off its 52-week low of $0.51.

Summary

MindWalk Holdings Corp. launched ReefIQ™, a new biological context layer powered by its HYFT® AI system, designed to enhance AI drug discovery by organizing fragmented biological data into a queryable, governed knowledge base.


Key Events · Product Development and Regulatory · HYFT

  • ReefIQ™ Platform Launch

    MindWalk Holdings Corp. introduced ReefIQ™, a new biological context layer for AI drug discovery and biologics development. This platform leverages the company's proprietary HYFT® technology to transform fragmented biological data into a governed, queryable context for AI reasoning workflows.

  • Enhances AI Drug Discovery

    ReefIQ™ is designed to bridge the gap where insights are lost due to disconnected data, preserving program learnings and providing a trustworthy foundation for AI models like LensAI™ to generate hypotheses and support decision-making in a regulated setting.

  • Strategic Product Expansion

    This launch operationalizes the HYFT information network, linking customer data to MindWalk's biological representation foundation and is intended to be foundational for future life-sciences engagements, building on existing contracted arrangements for LensAI™.


Analysis · HYFT · Life Sciences

This launch is a significant step in MindWalk's strategy to build robust BioIntelligence infrastructure. By providing a structured, queryable biological context, ReefIQ™ addresses a critical challenge in AI drug discovery: data fragmentation. This enhancement to their core HYFT® and LensAI™ platforms strengthens their competitive advantage and could accelerate drug development for their partners, potentially leading to increased adoption and revenue.

At the time of this filing, HYFT was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.1M. The 52-week trading range was $0.51 to $3.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HYFT - Latest Insights

HYFT
Jul 22, 2026, 6:36 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $1.28
Real-time Price: $1.35 info
Change: +$0.070 (+5%) info
Market Cap: $63.903M info
HYFT
Jul 22, 2026, 4:59 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $1.35 info
Change: -$0.050 (-4%) info
Market Cap: $63.903M info
HYFT
Jul 22, 2026, 4:54 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.35 info
Change: -$0.0714 (-5%) info
Market Cap: $63.903M info
HYFT
Jul 06, 2026, 10:10 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $1.35 info
Change: -$0.225 (-14%) info
Market Cap: $63.903M info
HYFT
Jul 01, 2026, 9:54 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $1.35 info
Change: -$0.240 (-15%) info
Market Cap: $63.903M info